Imunon (NASDAQ:IMNN – Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Imunon to post earnings of ($0.36) per share for the quarter.
Imunon Stock Performance
IMNN opened at $0.92 on Friday. The business’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $0.96. Imunon has a one year low of $0.53 and a one year high of $3.65. The stock has a market capitalization of $13.33 million, a P/E ratio of -0.49 and a beta of 2.03.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on IMNN. D. Boral Capital reiterated a “buy” rating and set a $29.00 target price on shares of Imunon in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research report on Thursday, December 19th.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Stories
- Five stocks we like better than Imunon
- What is the NASDAQ Stock Exchange?
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Overbought Stocks Explained: Should You Trade Them?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Do ETFs Pay Dividends? What You Need to Know
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
